PROJECT I ? ROLE OF BILIRUBIN IN PROTECTION AGAINST CARDIOMETABOLIC SYNDROME IN OBESITY PROJECT SUMMARY/ABSTRACT Obesity is a significant contributor to cardiometabolic diseases including hypertension, non-alcoholic fatty liver disease (NAFLD) and type II diabetes. All of these conditions contribute to the increased morbidity and mortality rates of obesity. Large population studies have demonstrated a negative correlation between serum bilirubin levels and development of cardiovascular disease and metabolic disorders including NAFLD and type II diabetes. Despite these correlative studies, the mechanism by which bilirubin protects against cardiometabolic disease is not known. We have exciting data demonstrating for the first time that bilirubin signals through nuclear hormone receptors such as peroxisome proliferator-activated receptor (PPAR?) to protect against cardiometabolic disorders. In addition, bilirubin can also inactivate glycogen synthase kinase-3? (GSK3?) to increase PPAR? target genes such as fibroblast growth factor 21 (FGF21); however, the specific roles of GSK3? inactivation/PPAR? activation to the anti-hypertensive, anti-steatotic and anti-diabetic actions of moderate hyperbilirubinemia are not known. Biliverdin reductase (BVR) is the enzyme responsible for reduction of biliverdin to bilirubin. It can generate bilirubin found in the plasma and generated inside the cell. The goal of this proposal is to test the central hypothesis that bilirubin and BVRA protect against obesity- induced hepatic steatosis, insulin resistance and hypertension via activation of the PPAR??signaling axis.
Aim 1 will test the hypothesis that chronic moderate hyperbilirubinemia resulting from bilirubin treatment or antagonism of hepatic UGT1A1 lowers blood pressure and reverses dietary obesity-induced hepatic steatosis and hepatic insulin resistance.
Aim 2 will test the hypothesis that moderate hyperbilirubinemia lowers blood pressure and reverses hepatic steatosis and insulin resistance via activation of PPAR?.
Aim 3 will test the hypothesis that that specific loss of hepatic bilirubin generation enhances hepatic steatosis and insulin resistance through a GSK3??mediated pathway that decreases PPAR? activity. Findings of these studies will have profound implications on development of moderate hyperbilirubinemia as a novel therapy for treatment of obesity-induced cardiometabolic disease. These studies will also determine the novel role of bilirubin as a nuclear hormone receptor signaling molecule and the role of this mechanism in protection against obesity- induced cardiometabolic diseases such as hypertension, NAFLD and type II diabetes.
PROJECT I ? ROLE OF BILIRUBIN IN PROTECTION AGAINST CARDIOMETABOLIC SYNDROME IN OBESITY PROJECT NARRATIVE Obesity is a significant contributor to cardiovascular diseases such as hypertension, non-alcoholic fatty liver disease (NAFLD) and type II diabetes all of which place a heavy burden on our economy. Bilirubin is a naturally produced bile pigment which has been correlated with decreased incidence of cardiovascular disease including hypertension, NAFLD and diabetes; however, the mechanism by which bilirubin may have these beneficial actions is unknown. This proposal will determine effective strategies for increasing bilirubin levels as well as determine the role of PPAR? in the beneficial actions of bilirubin to reverse obesity induced cardiovascular disease.
| Lindsey, Merry L; Mouton, Alan J; Ma, Yonggang (2018) Adding Reg3? to the acute coronary syndrome prognostic marker list. Int J Cardiol 258:24-25 |
| Lindsey, Merry L; Jung, Mira; Hall, Michael E et al. (2018) Proteomic analysis of the cardiac extracellular matrix: clinical research applications. Expert Rev Proteomics 15:105-112 |
| Brooks, Heddwen L; Lindsey, Merry L (2018) Guidelines for authors and reviewers on antibody use in physiology studies. Am J Physiol Heart Circ Physiol 314:H724-H732 |
| Mouton, Alan J; Rivera Gonzalez, Osvaldo J; Kaminski, Amanda R et al. (2018) Matrix metalloproteinase-12 as an endogenous resolution promoting factor following myocardial infarction. Pharmacol Res 137:252-258 |
| Sundararaghavan, Vikram L; Binepal, Sivjot; Stec, David E et al. (2018) Bilirubin, a new therapeutic for kidney transplant? Transplant Rev (Orlando) 32:234-240 |
| Roman, Richard J; Fan, Fan (2018) 20-HETE: Hypertension and Beyond. Hypertension 72:12-18 |
| do Carmo, Jussara M; da Silva, Alexandre A; Moak, Sydney P et al. (2018) Increased sleep time and reduced energy expenditure contribute to obesity after ovariectomy and a high fat diet. Life Sci 212:119-128 |
| Hall, Michael E (2018) Body Mass Index and Heart Failure Mortality: More Is Less? JACC Heart Fail 6:243-245 |
| Lindsey, Merry L (2018) Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling. Nat Rev Cardiol 15:471-479 |
| Turner, Paul A; Garrett, Michael R; Didion, Sean P et al. (2018) Spheroid Culture System Confers Differentiated Transcriptome Profile and Functional Advantage to 3T3-L1 Adipocytes. Ann Biomed Eng 46:772-787 |
Showing the most recent 10 out of 254 publications
